JosephHulihanMD

Neurophysiology

Principal at Paradigm Consulting, LLC

Dr. Hulihan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Drexel University College of Medicine/Hahnemann University HospitalResidency, Neurology, 1987 - 1990
Drexel University College of Medicine/Hahnemann University HospitalInternship, Internal Medicine, 1986 - 1987
Drexel University College of MedicineClass of 1986

PubMed

11 citations
Long-term treatment with ganaxolone for seizures associated with cyclin-dependent kinase-like 5 deficiency disorder: Two-year open-label extension follow-up.
Heather E Olson, Sam Amin, Nadia Bahi-Buisson, Orrin Devinsky, Eric D Marsh
Epilepsia. 2024-01-01
5 citations
EEG parameters as endpoints in epilepsy clinical trials - An expert panel opinion paper.
Jeffrey Buchhalter, Caroline Neuray, Jocelyn Y Cheng, O'Neill D'Cruz, Alexandre N Datta
Epilepsy Research. 2022-11-01
5 citations
Intravenous ganaxolone in pediatric super-refractory status epilepticus: A single hospital experience.
Rani K Singh, Rajdeep Singh, Alejandra Stewart, Katherine Van Poppel, Sarah Klinger
Epilepsy & Behavior Reports. 2022-01-01

Marinus Pharmaceuticals Submits New Drug Application (NDA) to FDA for Ganaxolone for the Treatment of Seizures Associated with CDKL5 Deficiency Disorder and Provides Pipeline UpdateAugust 3rd, 2021
Marinus Pharmaceuticals to Participate in 39th Annual J.P. Morgan Healthcare Conference and the H.C. Wainwright Bioconnect ConferenceJanuary 6th, 2021
Marinus Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for Ganaxolone for the Treatment of CDKL5 Deficiency Disorder (CDD)July 30th, 2020